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Introduction: Remission criteria of acromegaly are based on biochemical variables, i.e.,
normalization of increased hormone levels. However, the established reduction in Quality
of Life (QoL) is suggested to be independent of biochemical control. The aim of this study
was to test which aspects predict QoL best in acromegaly.
Methods/design: This is a prospective cohort study in 80 acromegalic patients, with a
cross-sectional and longitudinal part. The main outcome measure was health-related QoL,
measured by a generic and a disease-specific questionnaire (the SF-36 and AcroQoL).
Main predictors were age, gender, biochemical control, disease characteristics, treatment
modalities, and psychopathology.
Results: Our cohort of 80 acromegalics had a mean age 54.7±12.3 years with an aver-
age disease duration of 10.8±10.0 years. Ratio macro-/microadenoma was 54/26. In
adjusted mixed method models, we found that psychopathology significantly predicts QoL
in acromegaly (in models including the variables age, gender, disease duration, tumor
size, basal hormone levels, relevant treatment modalities, and relevant comorbidities),
with a higher degree of psychopathology indicating a lower QoL (depression vs. AcroQoL:
B=−1.175, p<0.001, depression vs. SF-36: B=−1.648, p<0.001, anxiety vs. AcroQoL:
B=−0.399, p<0.001, anxiety vs. SF-36: B=−0.661, p<0.001). The explained variances
demonstrate superiority of psychopathology over biochemical control and other variables
in predicting QoL in our models.
Discussion: Superiority of psychopathology over biochemical control calls for a more
extensive approach regarding diagnosing depression and anxiety in pituitary adenomas to
improve QoL. Depressive symptoms and anxiety are modifiable factors that might provide
valuable targets for possible future treatment interventions.
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INTRODUCTION
Objectives for health outcomes include reduction of mortality,
morbidity, and the improvement of Quality of Life (QoL) (1).
However, in patients with pituitary adenomas, such as
acromegaly, this third treatment goal remains often unfulfilled as
they report to have a markedly reduced QoL, which often persists
under biochemical control/remission (2–7).
Various factors have been suggested to be associated with
reduced QoL in pituitary disease, particularly acromegaly; how-
ever, there is no clear consensus in this regard.
The current consensus criteria for cure and remission of
acromegaly are based on biochemical variables, i.e., normalization
of elevated hormonal levels of the biomarkers growth hormone
(GH) and/or insulin like growth factor-1 (IGF-1) (8–10). How-
ever, the definition of such a “remission” remains insufficient with
regard to absolute recovery: a drawback of a purely biochemi-
cal approach is that there are strong indications that biochemical
control does not necessarily provide complete “cure” in patients’
view, since their health-related QoL remains reduced in most
patients with acromegaly.
However, there is no consensus on the value of these contribut-
ing factors. For instance, several articles reported biochemical
control to have no significant association with reduced QoL (11–
13), whereas other articles report exactly the opposite (14–16),
indicating a clear need for elucidation.
Psychopathological variables are candidate modifiable factors
to link pituitary disease, especially acromegaly, to a lower health-
related QoL. On the one hand, acromegaly is reported to be associ-
ated with neuropsychiatric comorbidities such as depressive symp-
toms (17) and anxiety (5, 18, 19). On the other hand, there is a clear
association between psychopathology and perceived QoL (20–22).
The aim of this study was therefore to test the predictive
impact of psychopathology (depressive symptoms and anxiety)
on health-related QoL in acromegalic patients.
For this purpose, a theoretical model (23) was applied
on acromegaly and tested in two primary data sets: (a) a
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cross-sectional cohort of 80 acromegalic patients, which was (b)




This is a prospective cohort study including two analytic parts: a
cross-sectional and prospective evaluation. For design and recruit-
ment of the initial cross-sectional cohort, see previous publications
from our group (18, 19). Six years after the cross-sectional evalua-
tion (baseline), a longitudinal evaluation was performed in which
the same patients were recontacted and asked to participate using
the same diagnostic instruments.
STUDY PARTICIPANTS
For the cross-sectional analyses, 80 acromegalic patients (response
rate 56%) were included. Patients were recruited at the Endocrine
Outpatient Clinic at the Max Planck Institute of Psychiatry and
the Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-
Universität Munich.
For the longitudinal analyses, patients were recontacted and
recruited accordingly. At both timepoints, patients were contacted
by a letter regarding the aim and design of the study. A fur-
ther request for participation was issued via telephone for initial
non-responders.
Thirty-six acromegalic patients (response rate 45%), were
included at the follow-up timepoint.
The project was approved by the medical ethics committee
of the Ludwig-Maximilians-Universität Munich; all patients gave
their written informed consent.
MEASUREMENT INSTRUMENTS
Clinical characteristics
Patients were given questionnaires with standardized psycho-
metric instruments, which allowed assessment of disease-related
variables, therapy history, symptoms, tumor characteristics,
comorbidities and current complaints, and evaluation of psy-
chopathological symptoms. Patients were seen either at the Max
Planck Institute for Psychiatry or at the Ludwig-Maximilians-
Universität Munich for a standardized clinical assessment, which
included a physical examination and laboratory analyses. Addi-
tional information was retrieved from the patient files if necessary.
Laboratory measurements
Biochemical control (dichotomous classification) was based on
a single serum sample of patients with confirmed disease. Bio-
chemical control of acromegaly was defined as (1) GH levels
<1µg/l during a glucose-tolerance test over 2 h and (2) IGF-1
levels within 2 SD of an age- and gender-adjusted standardized
sample (8).
Pituitary function was routinely assessed in all patients on a
yearly basis, with basal fasting measurements of IGF-1, thyroid
stimulating hormone (TSH), free thyroxine, total triiodothyro-
nine, luteinizing hormone (LH), follicle-stimulating hormone
(FSH), prolactin, and testosterone (men) or estradiol (female).
Moreover, stimulation tests were administered including short
ACTH test, GHRH/arginine test, and insulin hypoglycemia test,
if indicated. All patients were studied under optimal replacement
therapy (24).
Neuropsychiatric assessment
Quality of Life was measured using the specifically designed instru-
ment AcroQoL (range 0–110) (25), and the general instrument
SF-36 (range 0–100) (26, 27). All QoL instruments were arranged
to have higher scores reflecting a better QoL.
The following neuropsychiatric variables were assessed: depres-
sive symptoms [Becks Depression Inventory (BDI) (28), range 0–
63] and anxiety [State-Trait Anxiety Inventory (STAI) (29), range
40–160]. Neuropsychiatric scoring-instruments were arranged to
have higher scores reflect greater disability.
All questionnaires were self-completed.
STATISTICAL ANALYSIS
All analyses were performed with the Statistical Package for the
Social Sciences 20.0 Software (SPSS 20.0).
DESCRIPTIVE ANALYSES
Differences between biochemically controlled and uncontrolled
patients for demographic variables were analyzed using χ2-tests
and independent samples t -tests. Significance was set at the 0.05
level.
STATISTICAL MODELS
Six-Block linear regression analyses were carried out to assess
the contribution of different variables to the outcome QoL.
Block 1 contained age and gender, block 2 contained tumor
Table 1 | Demographic variables according to disease control.
Uncontrolled Controlled P*
Subjects at baseline (N ) 80
31 49
Subjects at follow-up 36
15 21




Disease duration (years)a 10.8±10.0
10.6±10.6 11.2±9.6 0.822
% Maleb 46.3 (37)
54.8 (17) 40.8 (20) 0.220
% Macroadenomab 68.8 (55)
80.6 (25) 61.2 (30) 0.068
Basal GHc 2.8±5.0
5.3±7.1 1.1±0.9 0.003
*p-Values computed using independent t-tests, chi square tests for the variables
% Male and % Macroadenoma.
aMean±SD,
b% (N).
cBasal hormonal levels: serum GH for acromegaly (µg/l).
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Table 2 | Association of psychopathology/biochemical control and QoL at baseline.
Disease (scale) Variable B (SE) p* ∆R2 after correctiona Model R2
Acromegaly (AcroQoL)b Depressive symptoms −1.175 (0.170) <0.001 0.256 0.688
Biochemical control −1.157 (3.009) 0.702 0.001
Anxiety −0.399 (0.089) <0.001 0.147 0.578
Biochemical control −0.546 (3.497) 0.876 <0.001
Acromegaly (SF-36)c Depressive symptoms −1.648 (0.256) <0.001 0.279 0.618
Biochemical control 2.724 (4.497) 0.547 0.002
Anxiety −0.661 (0.109) <0.001 0.258 0.598
Biochemical control 3.126 (4.614) 0.501 0.003
*p-Values were computed using linear regression.
aAll models carried a correction for age, gender, disease duration, basal hormone levels and tumor size.
Additional correction for:
bradiation, pathological glucose intolerance and arthralgia,
cradiation, arthralgia.
Bold font marks those results with statistical significance.
size (dichotomous: macro- vs. microadenoma), basal GH
levels, and disease duration, block 3 contained treatment
types [dichotomous: surgery, radiation therapy, octreotide, lan-
reotide, dopamine-agonists (bromocriptin, lisuride, cabergoline,
quinagolide), pegvisomant], block 4 contained comorbidities
(dichotomous: arrhythmia, cardiomyopathy, cerebrovascular dis-
eases, arterial hypertension, coronary artery disease, history of
myocardial infarction, arthralgia, arthropathy, carpal tunnel syn-
drome, diabetes mellitus type 2, pathological glucose-tolerance,
pituitary insufficiency, sleep apnea, lung diseases, cancer), and
block 5 contained the psychopathological variables (depressive
symptoms, anxiety). Separate analyses were carried out for depres-
sive symptoms and anxiety (block 5) due to large correlations
(Pearson’s r = 0.713, p< 0.001). Block 6 contained the variable
biochemical control as a predictor. A forced entry method was used
for block 1, 2, 5, and 6 as we deemed inclusion of these variables,
a basic requirement for our model. A stepwise forward likelihood
ratio method was used for blocks 3 and 4 to include only those
predictors that carried significant predictive value. The likelihood
ratio method is preferable over the other stepwise methods (30).
For the longitudinal analyses to determine predictors of long-
term QoL, linear mixed-effect models with a first-order autore-
gressive covariance matrix for repeated effects were used. Linear
mixed-effects models allow a flexible length of follow-up for
separate patients and account for within-patient variations (31,
32). Separate regression coefficients and intercepts were created
for each individual patient. To investigate the influence of psy-
chopathology on progression of QoL, the interaction between
time and depressive symptoms/anxiety was investigated. A sim-
ilar approach was taken to investigate if biochemically controlled
patients progress differently throughout time in terms of QoL than
their uncontrolled counterparts by investigating an interaction
between time and biochemical control. Variables that yielded a
significant contribution in the baseline model were implemented
as factors/covariates in all longitudinal models, as well as age,
gender, disease duration, and basal hormonal levels, to account
for confounding. Normality was confirmed by examining normal
probability plots. Significance was set at the 0.05 level.
FIGURE 1 | Distribution of QoL according to scale (mean standardized
predicted values), and biochemical status. Error bars represent 95% CI.
MISSING VALUES
If 15% or more of the data from a questionnaire or scale was
missing, data from that variable was excluded from analysis.
Remaining missing values were filled in according to the corre-
sponding scoring instructions or by using the median from the
separate items if the scoring instructions lacked a suggestion for
dealing with missing values. An exception was made for the covari-
ate biochemical control; missing data in this domain resulted in
exclusion from analysis for that patient.
RESULTS
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS
Mean age for the total acromegalic cohort was 54.7± 12.3 years
with an average disease duration of 10.8± 10.0 years. Fifty-four
patients had a macroadenoma, 26 patients had a microadenoma.
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FIGURE 2 | (A) Distribution of QoL in acromegaly (standardized predicted values) relative to depressive symptoms with fitted trend-line. (B) Distribution of QoL
in acromegaly (standardized predicted values) relative to anxiety with fitted trend-line.
At baseline, 31 patients were biochemically uncontrolled, and
49 patients were biochemically controlled. Mean basal hor-
monal level was 2.8± 5.0µg/l for GH and 214.2± 161.2 nmol/l,
for IGF-1.
For the follow-up analyses, 36 patients participated, mean
follow-up time was 7.1± 0.7 years – 15 patients remained
uncontrolled, whereas 21 patients were biochemically controlled
at follow-up. Demographic and clinical characteristics (cross-
sectional and longitudinal) are shown in Table 1.
ASSOCIATION BETWEEN PSYCHOPATHOLOGY/BIOCHEMICAL
CONTROL AND QoL AT BASELINE
At baseline, our analyses demonstrate that depressive symptoms
significantly predicted QoL measured by AcroQoL (p< 0.001) and
SF-36 (p< 0.001) in acromegaly in a model including age, gen-
der, disease duration, basal GH levels, tumor size, and possible
treatment modalities and comorbidities as covariates. Negative
coefficients reflect a greater amount of depressive symptoms to be
indicative of a greater impairment of QoL. The amount of vari-
ance explained (∆R2) by depressive symptoms is 0.261 for the
AcroQoL and 0.285 for the SF-36, which was the highest variance
among all covariates in models explaining a variance (R2) of 0.637
(AcroQoL) and 0.577 (SF-36).
Similarly, results demonstrate anxiety to be significantly pre-
dictive for the AcroQoL (p< 0.001) and the SF-36 (p< 0.001) in
acromegaly. Negative coefficients reflect a greater amount of anx-
iety to be indicative of a greater impairment of QoL.∆R2 is 0.149
for AcroQoL and 0.256 for SF-36 in models with an R2 of 0.505
(AcroQoL) and 0.543 (SF-36).
Biochemical control was not significantly associated with QoL
in acromegaly.
Coefficients, p-values, and explained variances (R2) are shown
in Table 2, Figure 1 (biochemical control), and Figure 2 (psy-
chopathology).
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ASSOCIATION BETWEEN PSYCHOPATHOLOGY/BIOCHEMICAL
CONTROL AND QoL AT FOLLOW-UP
At follow-up (longitudinal analyses), results demonstrate depres-
sive symptoms to be significantly predictive of QoL measured by
AcroQoL (p< 0.001) and SF-36 (p= 0.001) in acromegaly in a
similar model with age, gender, disease duration, basal GH levels,
tumor size,and possible treatment modalities and comorbidities as
covariates. Similarly, results demonstrate anxiety to be predictive
of QoL measured by AcroQoL (p< 0.001) and SF-36 (p< 0.001)
in acromegaly. Negative estimates reflect a greater amount of
depressive symptoms/anxiety to be indicative of impaired QoL.
Biochemical control was otherwise not significantly predictive
of QoL in other analyses.
Estimates and p-values are shown in Table 3.
Table 3 | Association of psychopathology/biochemical control and
QoL at follow-up.
Disease (scale) Variable Estimate (SE)a P*
Acromegaly
(AcroQoL)b
Depressive symptoms −1.213 (0.154) <0.001
Biochemical control −1.973 (2.910) 0.500
Anxiety −0.405 (0.074) <0.001
Biochemical control −1.281 (3.473) 0.713
Acromegaly
(SF-36)c
Depressive symptoms −1.601 (0.236) 0.001
Biochemical control 2.420 (4.072) 0.555
Anxiety −0.666 (0.087) <0.001
Biochemical control 3.647 (4.471) 0.418
*p-Values computed using linear mixed models.
aAll models carried a correction for age, gender, disease duration, basal hormone
levels, and tumor size.
Additional correction for:
bradiation, pathological glucose intolerance and arthralgia,
cradiation, arthralgia.
Bold font marks those results with statistical significance.
Table 4 | Association of psychopathology/biochemical control and
progression of QoL.
Disease (scale) Variable Estimate (SE)a P*
Acromegaly
(AcroQoL)b
Depressive symptoms*time −0.107 (0.222) 0.632
Biochemical control*time 0.272 (3.244) 0.934
Anxiety*time −0.005 (0.041) 0.900
Biochemical control*time 0.434 (3.743) 0.908
Acromegaly
(SF-36)c
Depressive symptoms*time −0.121 (0.335) 0.922
Biochemical control*time −1.512 (4.823) 0.926
Anxiety*time −0.052 (0.047) 0.274
Biochemical control*time −1.712 (4.271) 0.691
*p-Values computed using linear mixed models.
aAll models carried a correction for age, gender, disease duration, basal hormone
levels and tumor size.
Additional correction for:
bradiation, pathological glucose intolerance, and arthralgia,
cradiation, arthralgia.
ASSOCIATION BETWEEN PSYCHOPATHOLOGY/BIOCHEMICAL
CONTROL AND PROGRESSION OF QoL THROUGHOUT TIME
Interaction between time and depressive symptoms, time and
anxiety, and time and biochemical control was not significantly
associated with QoL in acromegaly, indicating no influence of
depressive symptoms, anxiety, or biochemical control on the pro-
gression of QoL throughout time. Estimates and p-values are
shown in Table 4 and Figure 3.
DISCUSSION
The aim of this study was to analyze the relative impact of previ-
ously described predictors in relation to psychopathology on the
patient-related health outcome “QoL” in acromegaly.
Since most of the known variables associated with a poor
health-related QoL in acromegaly are not modifiable (such as
age, gender, disease duration and tumor size), we focused on psy-
chopathology, which would reflect a treatable component that is
commonly underdiagnosed.
Although the relationship between QoL and psychopathology
has been described before (20–22) in parallel to a solid recogni-
tion of reduced QoL in pituitary adenomas and acromegaly (2,
FIGURE 3 | Progression of QoL (mean values) in acromegaly relative to
biochemical status. Error bars represent 95% CI.
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3), we found that the marked reduction of QoL is driven dom-
inantly by psychopathology rather than biochemical control or
other factors, which is new information. A potential reason for
this observation is that hormonal factors in acromegaly are not
necessarily noticeable on a daily basis whereas psychopathological
factors are much more dominantly present. The overbearing char-
acter of psychopathology may therefore exert a larger influence on
a patient’s QoL than the less obvious biochemical control.
It has been previously described that psychopathology is an
independent predictor of QoL rather than a masked way of mea-
suring QoL in pituitary patients (6). The scientific implications
of our research are augmented by the World Health Organization,
which has long recognized the crucial role of QoL in patient-
oriented clinical approaches (33). Moreover, a clear association
between high QoL scores and a longer survival duration in can-
cer patients has been described previously (34). These results are
in agreement with an earlier study that argues the importance
of adding a QoL component rather than sole biochemical con-
siderations in order to improve patient management (35). The
findings that psychopathology, rather than biochemical control,
drives reduced QoL based on the demonstrated explained vari-
ances complements the well-recognized reduction of QoL in pitu-
itary adenomas and leads to our recommendation to place greater
emphasis on the role of psychopathology in acromegaly.
Aside from scientific implications, key in the clinical application
of this research is the finding that important predictors of reduced
QoL are depressive symptoms and anxiety, which are essentially
modifiable predictors. A more complex treatment strategy includ-
ing a more extensive psychopathological evaluation and therapy
may be an attractive possibility to improve patient management
in pituitary adenomas and especially acromegaly.
STRENGTHS AND LIMITATIONS
Strengths of our study are the longitudinal design, the two-center
approach, the large amount of potential confounders that are
accounted for and the usage of validated and disease-specific
questionnaires. Furthermore, our study yields new and additional
information to expand on previous research and has obvious
clinical relevance.
Limitations of our study as in each and every longitudinal study
are the potential bias that is introduced due to a preferential “loss-
to-follow-up.” Reasons for this non-response were, e.g., disinterest
to participate in a large questionnaire, feeling of being cured, and
associated disinterest to participate in medical research, deterio-
ration, and associated inability to fill out questionnaires or death.
The reasons for non-compliance in our study were not system-
atically studied. Additionally, not all potential influential factors
have been included in the study, e.g., no available data on anti-
depressant drug-usage, which may be influential on the severity of
the depressive symptoms.
Future research should focus on improving the response rates
and validate the observed findings in preferably larger cohorts.
Systematic reviews of the literature should attest whether there are
other (ideally modifiable) predictors of QoL in acromegaly aside
from psychopathology to identify multiple targets for improving
QoL (research in progress). Trials with modifying these variables
could ultimately verify their clinical applicability (protocol sub-
mitted for ethical vote, phase 4 trial EudraCT 2014-000265-43).
CONCLUSION
Results indicate biochemical control of acromegaly to be unassoci-
ated with both generic and disease-specific QoL. Psychopathology
seems to predominantly drive reduced QoL in acromegaly. Hence,
we recommend scrutinous systematic screening for psychopathol-
ogy leading to subsequent specific therapy in acromegaly to test
the effect on improving QoL.
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